A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates the immune cells.

"Declarations Ethics approval and consent to participateClinical human melanoma tissue, PBMC and animal experiments were performed in accordance with guidelines and approved by the Shenzhen Institutional Animal Care and Guangdong Provincial Medical Laboratory Animal Center (License No. 16 (2018)). Human melanoma tissue and PBMC were approved and collected from Shenzhen People's Hospital, and reviewed by the hospital ethics committee according to the Declaration of Helsinki. The registration of Approval No. 2021–466-01. Consent for publicationAll authors have agreed to publish this manuscript. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding We were supported by the National Natural Science Foundation of China (81872368, 81641051); Shenzhen Development and Reform Commission Subject Construction Project [2017]1434."